Gliclazide (29), a member of the sulfonylurea class of drugs, has demonstrated efficacy in mitigating intestinal inflammation in rats with ulcerative colitis through modulation of PPARγ, NF-κB, and MAPK signaling pathways in preclinical studies. Here, PPARG is linked to ulcerative colitis.